State of Tennessee Department of Treasury Sells 6,235 Shares of DaVita Inc. (NYSE:DVA)

State of Tennessee Department of Treasury reduced its stake in DaVita Inc. (NYSE:DVA - Free Report) by 18.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,742 shares of the company's stock after selling 6,235 shares during the period. State of Tennessee Department of Treasury's holdings in DaVita were worth $3,999,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Wellington Management Group LLP lifted its position in shares of DaVita by 9.1% during the 4th quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock worth $405,000 after buying an additional 227 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of DaVita by 134.6% during the 3rd quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock valued at $8,885,000 after purchasing an additional 31,502 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in DaVita by 201.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company's stock valued at $11,159,000 after buying an additional 49,885 shares in the last quarter. Hussman Strategic Advisors Inc. increased its holdings in shares of DaVita by 200.0% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company's stock worth $3,769,000 after buying an additional 16,800 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock worth $39,712,000 after buying an additional 12,339 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DVA has been the subject of several research analyst reports. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Finally, Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $166.33.

DaVita Trading Down 0.5 %

DVA traded down $0.72 during trading on Thursday, hitting $140.83. The company's stock had a trading volume of 187,163 shares, compared to its average volume of 835,818. DaVita Inc. has a twelve month low of $131.27 and a twelve month high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The stock's fifty day moving average price is $146.11 and its 200-day moving average price is $154.92. The firm has a market capitalization of $11.27 billion, a P/E ratio of 13.13, a PEG ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.